One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
What are important predictors of perceived stigmatization in patients with psoriasis? Commentary to ‘Significance of chronic pruritus for intrapersonal burden and interpersonal experiences of stigmatization and sexuality in patients with psoriasis’ by R. Sommer et al.
J. Kupfer, C. Schut
doi : 10.1111/jdv.17299
Volume 35, Issue 7 p. 1418-1419
The World Health Organization (WHO) passed a resolution on psoriasis in 2014, which included the following sentence: ‘All Member States recognized the burden of psoriasis and committed to increase their efforts to fight the stigma and unnecessary exclusion of people living with psoriasis’.1 The psychosocial component of the disease was thus recognized and explicitly mentioned. Another result of this conference was the aim to publish a ‘Global Report on Psoriasis’, which is available for 5 years by now. In this report, among other aspects psychological problems associated with psoriasis are illustrated. Despite new, often effective treatment options such as biologicals, psoriasis is still considered a highly stigmatizing disease. A questionnaire-based study, in which healthy subjects were shown images of different dermatoses, revealed that psoriasis was regarded as more bothersome than any other investigated dermatosis except for herpes labialis and that psoriasis was the skin condition that provoked feeling pity most often.2
Hidradenitis suppurativa-specific, patient-reported outcome measures
C.C. Zouboulis, P.V. Chernyshov
doi : 10.1111/jdv.17306
Volume 35, Issue 7 p. 1420-1421
Monitoring of the effects of interventional and treatment trials requires the use of objective outcome measurement instruments (OMI), with criteria endorsed by healthcare professional experts and validated on relevant prospective studies.1 Moreover, the validity of meta-analysis and data comparison from different studies is dependent on OMI quality. On the other hand, there is concomitantly increasing interest on patient-reported outcome measures (PROM), with criteria endorsed by patients, to assess the quality of life (QoL) along the course of the disease and its modification by treatment, especially in chronic diseases.
Pioneers in Dermatology and Venereology: an interview with Professor Xue-Jun Zhu
X.-J. Zhu
doi : 10.1111/jdv.17367
Volume 35, Issue 7 p. 1422-1423
Global publication productivity in dermatology: a bibliometric description of the past and estimation of the future
L. Gantenbein, P. Arora, A. Navarini, O. Brandt, S.M. Mueller
doi : 10.1111/jdv.17196
Volume 35, Issue 7 p. 1424-1433
In the past two centuries, generations of dermatologists around the world have created an enormous number of publications. To our knowledge, no bibliometric analysis of these publications has been performed so far, nor have registered trials been analysed to anticipate future publication trends.
2021 European Guideline on the management of proctitis, proctocolitis and enteritis caused by sexually transmissible pathogens
H.J.C. de Vries, A.V. Nori, H. Kiellberg Larsen, A. Kreuter, V. Padovese, S. Pallawela, M. Vall-Mayans, J Ross
doi : 10.1111/jdv.17269
Volume 35, Issue 7 p. 1434-1443
This guideline intents to offer guidance on the diagnosis and management of patients with gastrointestinal symptoms and a suspected sexually transmitted cause. Proctitis is defined as an inflammatory syndrome of the anal canal and/or the rectum. Infectious proctitis can be sexually transmitted via genital–anal mucosal contact, but some also via digital contact and toys. Neisseria gonorrhoeae, Chlamydia trachomatis (including lymphogranuloma venereum), Treponema pallidum and herpes simplex virus are the most common sexually transmitted anorectal pathogens. Shigellosis can be transferred via oral–anal contact and may lead to proctocolitis or enteritis. Although most studies on these infections have concentrated on men who have sex with men (MSM), women having anal intercourse may also be at risk. A presumptive clinical diagnosis of proctitis can be made when there are symptoms and signs, and a definitive diagnosis when the results of laboratory tests are available. The symptoms of proctitis include anorectal itching, pain, tenesmus, bleeding, constipation and discharge in and around the anal canal. The majority of rectal chlamydia and gonococcal infections are asymptomatic and can only be detected by laboratory tests. Therefore, especially when there is a history of receptive anal contact, exclusion of anorectal infections is generally indicated as part of standard screening for sexually transmitted infections (STIs). Condom use does not guarantee protection from STIs, which are often spread without penile penetration. New in this updated guideline is: (i) lymphogranuloma venereum proctitis is increasingly found in HIV-negative MSM, (ii) anorectal Mycoplasma genitalium infection should be considered in patients with symptomatic proctitis after exclusion of other common causations such N. gonorrhoeae, C. trachomatis, syphilis and herpes, (iii) intestinal spirochetosis incidentally found in colonic biopsies should not be confused with syphilis, and (iv) traumatic causes of proctitis should be considered in sexually active patients.
Position statement: The need for EU legislation to require disclosure and labelling of the composition of medical devices
A. Herman, W. Uter, T. Rustemeyer, M. Matura, K. Aalto-Korte, J. Duus Johansen, M. Gonçalo, I.R. White, A. Balato, A.M. Giménez Arnau, K. Brockow, C.G. Mortz, V. Mahler, A. Goossens, on behalf of the ESCD, EECDRG, EADV Contact Dermatitis Task Force, EAACI
doi : 10.1111/jdv.17238
Volume 35, Issue 7 p. 1444-1448
In recent years, skin reactions secondary to the use of medical devices (MD), such as allergic contact dermatitis have increasingly been observed (e.g. to continuous blood sugar monitoring systems, insulin pumps, wound dressings, medical gloves, etc.): this is regarded as a developing epidemic. Lack of labelling of the composition of MD, as well as frequent lack of cooperation of manufacturers to disclose this relevant information, even when contacted by the clinician for the individual case of an established adverse reaction, significantly impede patient care.
Management of albinism: French guidelines for diagnosis and care
E. Moreno-Artero, F. Morice-Picard, D. Bremond-Gignac, I. Drumare-Bouvet, C. Duncombe-Poulet, S. Leclerc-Mercier, H. Dufresne, J. Kaplan, B. Jouanne, B. Arveiler, A. Taieb, S. Hadj-Rabia
doi : 10.1111/jdv.17275
Volume 35, Issue 7 p. 1449-1459
Albinism is a worldwide genetic disorder caused by mutations in at least 20 genes, identified to date, that affect melanin production or transport in the skin, hair and eyes. Patients present with variable degrees of diffuse muco-cutaneous and adnexal hypopigmentation, as well as ocular features including nystagmus, misrouting of optic nerves and foveal hypoplasia. Less often, albinism is associated with blood, immunological, pulmonary, digestive and/or neurological anomalies. Clinical and molecular characterizations are essential in preventing potential complications. Disease-causing mutations remain unknown for about 25% of patients with albinism. These guidelines have been developed for the diagnosis and management of syndromic and non-syndromic forms of albinism, based on a systematic review of the scientific literature. These guidelines comprise clinical and molecular characterization, diagnosis, therapeutic approach and management.
Photoprotection according to skin phototype and dermatoses: practical recommendations from an expert panel
T. Passeron, H.W. Lim, C.-L. Goh, H.Y. Kang, F. Ly, A. Morita, J. Ocampo Candiani, S. Puig, S. Schalka, L. Wei, B. Dréno, J. Krutmann
doi : 10.1111/jdv.17242
Volume 35, Issue 7 p. 1460-1469
Increasing evidence on the impact of the different wavelengths of sunlight on the skin demonstrates the need for tailored recommendations of sunscreen according to skin phototype and dermatoses, which is now possible due to advances in the filters and formulations of sunscreens. A selective literature search was performed by an international expert panel, focusing on the type of sunscreen to recommend for photoaging, skin cancers, photodermatoses, pigmentary disorders and skin inflammatory disorders. Protection against ultraviolet (UV)B is especially important for light skin as there is a high risk of sunburn, DNA damage and skin cancers. Darker skin may be naturally better protected against UVB but is more prone to hyperpigmentation induced by visible light (VL) and UVA. Protection against UVA, VL and infrared A can be helpful for all skin phototypes as they penetrate deeply and cause photoaging. Long-wave UVA1 plays a critical role in pigmentation, photoaging, skin cancer, DNA damage and photodermatoses. Adapting the formulation and texture of the sunscreen to the type of skin and dermatoses is also essential. Practical recommendations on the type of sunscreen to prescribe are provided to support the clinician in daily practice.
Dermoscopic and trichoscopic features of primary cutaneous lymphomas – systematic review
M. S?awi?ska, M. Soko?owska-Wojdy?o, B. Olszewska, R.J. Nowicki, M. Sobjanek, I. Zalaudek
doi : 10.1111/jdv.17219
Volume 35, Issue 7 p. 1470-1484
Dermoscopy and trichoscopy are non-invasive methods used as auxiliary tools in diagnostics of different dermatoses. To date, no systematic review concerning the utility of dermoscopy and trichoscopy in the diagnostics of primary cutaneous lymphomas has been published. The aim of this study was to summarize the current state of knowledge on this topic based on systematic search of PubMed database and related references published before 8th of August 2020. Besides dermoscopic features, type of dermoscope, polarization mode, magnification, number of cases and histopathological correlation were analysed. A total of 34 records were included into the final analysis, evaluating 141 patients diagnosed with primary cutaneous T-cell lymphomas and 70 patients with primary cutaneous B-cell lymphomas. Most of the analysed records evaluated dermoscopic features (n = 206); trichoscopy was analysed in only 5 cases. Structures most commonly observed in classical mycosis fungoides (n = 108) were fine short linear vessels/linear vessels, spermatozoa-like vessels and orange-yellow patchy areas. In folliculotropic mycosis fungoides (n = 12), most frequently observed were comedonal lesions/comedo openings/central keratotic plugs and white halo around hair follicles/perifollicular accentuation. Primary cutaneous marginal zone B-cell lymphoma (n = 42) and primary cutaneous follicle centre lymphoma (n = 20) most commonly presented with salmon-coloured background and fine short/linear irregular/serpentine vessels. For other PCL, with less than 10 cases reported in the analysed records, details have been provided in the article. Most observations analysed in this systematic review rely on findings from case reports/case series (with the level of evidence V) and lack a control group. A few studies provided information concerning technical aspects of dermoscopic/trichoscopic examination. The role of dermoscopy/trichoscopy in diagnostics of cutaneous lymphomas requires further studies, especially in entities where dermoscopic features have been described in only single or a few cases. However, it seems that this practical, accessory tool in future may provide additional clues during clinical assessment.
Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose
A. Villani, G. Fabbrocini, J. Ocampo-Candiani, A. Ruggiero, S.S. Ocampo-Garza
doi : 10.1111/jdv.17216
Volume 35, Issue 7 p. 1485-1492
Topical minoxidil has been used for many years as treatment for different hair disorders. Even though it is an effective therapy, many patients show poor compliance due to the cosmesis, cost and side-effects. During the last few years, low-dose oral minoxidil has proven to be an alternative for patients with alopecia. We performed a literature search including all the articles that used oral minoxidil as a primary treatment in various hair diseases in order to evaluate the efficacy and safety of low-dose oral minoxidil as an alternative to topical minoxidil. Androgenetic alopecia was the most common studied condition, but others included telogen effluvium, tractional alopecia, postchemotherapy-induced alopecia, monilethrix, loose anagen hair syndrome, alopecia areata and scarring alopecias (frontal fibrosing alopecia and lichen planopilaris). Larger randomized comparative studies including standardized objective measurements should be done in order to clarify the best treatment protocol, including dosage and treatment duration. Oral minoxidil has proven to be a successful and well-tolerated alternative for patients with hair loss, including those with poor adherence to other therapies. Different dosing regimens have been utilized in scarring and non-scarring alopecia, varying from 0.25 to 5 mg daily. Higher doses have not been studied in men or women. Available literature suggests women require lower doses, from 0.25 to 2.5 mg daily, while men require higher doses for maximal efficacy, from 1.25 to 5 mg a day.
Stigma in visible skin diseases – a literature review and development of a conceptual model
N. Germain, M. Augustin, C. François, K. Legau, N. Bogoeva, M. Desroches, M. Toumi, R. Sommer
doi : 10.1111/jdv.17110
Volume 35, Issue 7 p. 1493-1504
The burden of visible skin diseases (VSDs) includes not only physical symptoms but also psychosocial consequences such as depression, anxiety, impaired quality of life and low self-esteem. Stigmatization was shown to play a major role in people with skin diseases. The aim of the study was to review the evidence for the components, drivers and impacts of (self-)stigma, and to organize the data into a series of conceptual models. A targeted literature search was conducted to identify studies on (self-)stigma in relation to VSD. Conceptual models of stigma in VSDs were developed from existing generic conceptual models for VSD and of generic conceptual models of stigma and were refined after discussion with a board of experts, patient advocacy groups, clinicians and researchers. A total of 580 references were identified, of which 56 references were analysed and summarized. Two conceptual models of stigma were identified: one with external stigma and self-stigma dimensions, the other for self-stigma in mental health. These models were adapted to allow a complete description of stigma in VSDs. For this, a distinction was made between ‘discrimination’ and ‘impact’. Finally, five models were developed: macro-overview; stigma, impact and socio-demographics; stigma, impact and disease characteristics; stigma, impact and quality of life; and stigma, impact and coping. Gaps were identified in available quantitative evidence. To our knowledge, this is the first conceptual model of stigma in VSDs. The model will help to standardize evaluation of stigma and to enhance empirical evaluation of anti-stigma interventions in VSDs. Further research should be conducted to develop a more complete model in stigma due to significant gaps in existing evidence, particularly including the stigma in others (external stigma) and also to cover a broader range of VSDs as their impact on particular dimensions of stigma differs.
Topical therapy of atopic dermatitis with a focus on pimecrolimus
T. Luger, A.S. Paller, A.D. Irvine, R. Sidbury, L.F. Eichenfield, T. Werfel, T. Bieber
doi : 10.1111/jdv.17272
Volume 35, Issue 7 p. 1505-1518
Atopic dermatitis (AD) is a chronic and relapsing, inflammatory skin disease characterized by impaired skin barrier function and immune system dysregulation that results in dryness, skin microbiome dysbiosis and intense pruritus. It is highly heterogeneous, and its management is demanding. Patients with AD are at greater risk of comorbidities such as attention-deficit hyperactivity disorder as well as other atopic diseases. Early-onset AD cases typically improve or resolve in late childhood; however, it is proposed that the prevalence of persistent or adult-onset AD is higher than previously thought. Basic therapy consists of emollient application and trigger avoidance, and when insufficient, topical corticosteroids (TCS) are the first-line treatment. However, corticophobia/steroid aversion and TCS side-effects, particularly on sensitive skin areas, lead to low compliance and insufficient disease control. Several long- and short-term randomized controlled and daily practice studies have demonstrated that topical calcineurin inhibitors, such as pimecrolimus, have similar anti-inflammatory effects to low-to-medium strength TCS, reduce pruritus and improve the quality of life of patients. In addition, pimecrolimus does not cause skin atrophy, is steroid-sparing and has a good safety profile, with no evidence for an increased risk of malignancies or skin infections. In general, pimecrolimus cream is well-accepted and well-tolerated, encouraging patient adherence and leading to its use by many physicians as a preferred therapy for children and sensitive skin areas.
Estimating the potential impact of interventions to reduce over-calling and under-calling of melanoma
M. Gibson, R.A. Scolyer, H.P. Soyer, P. Ferguson, K. McGeechan, L. Irwig, K.J.L. Bell
doi : 10.1111/jdv.17189
Volume 35, Issue 7 p. 1519-1527
Pathologists sometimes disagree over the histopathologic diagnosis of melanoma. ‘Over-calling’ and ‘under-calling’ of melanoma may harm individuals and healthcare systems.
Incidence and survival of cutaneous melanoma in Belgium and the Netherlands from 2004 to 2016: striking differences and similarities of two neighbouring countries
B. Reyn, E. Van Eycken, M. Louwman, K. Henau, K. Schreuder, L. Brochez, M. Garmyn, N.A. Kukutsch
doi : 10.1111/jdv.17197
Volume 35, Issue 7 p. 1528-1535
Cutaneous melanoma (CM) is a multifactorial disease, with both environmental and genetic factors involved. The incidence of CM has risen rapidly during the last decades, making it a growing public health problem.
Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004-2017
A. Langenbruch, N. Mohr, N. Kirsten, K. Reich, R. von Kiedrowski, K. Str?mer, U. Mrowietz, M. Augustin
doi : 10.1111/jdv.17220
Volume 35, Issue 7 p. 1536-1542
In the study series PsoHealth first data from 2004/05 showed a poor quality of health care for psoriasis in Germany. Most patients lacked sufficient care and only a minor proportion received systemic drugs. Since 2007, a national psoriasis programme has been conducted.
Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial
A. Wollenberg, T. Nakahara, C. Maari, K. Peris, P. Lio, M. Augustin, J.I. Silverberg, M.J. Rueda, A.M. DeLozier, E. Pierce, F.E. Yang, L. Sun, S. Ball, M. Tauber, C. Paul
doi : 10.1111/jdv.17278
Volume 35, Issue 7 p. 1543-1552
Baricitinib is an oral, selective, reversible Janus kinase 1/2 inhibitor approved in the European Union and Japan and under investigation in the United States for treatment of atopic dermatitis (AD).
Significance of chronic pruritus for intrapersonal burden and interpersonal experiences of stigmatization and sexuality in patients with psoriasis
R. Sommer, M. Augustin, C. Hilbring, S. St?nder, M. Hubo, H.J. Hutt, C.C. von Stülpnagel, N. da Silva
doi : 10.1111/jdv.17188
Volume 35, Issue 7 p. 1553-1561
60–90% of patients with psoriasis suffer from pruritus and 65% report itching as one of the most burdensome symptoms, raising significant quality of life (QoL) impairments. However, pruritus is not only an intrapersonal symptom but also a psychosocial interactive phenomenon and little is known about the effects of itching on interpersonal experiences.
Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ? 16) analysis of randomized phase 2B study
J.I. Silverberg, A. Pinter, A. Alavi, C. Lynde, J.-D. Bouaziz, A. Wollenberg, D.F. Murrell, S. Alpizar, V. Laquer, K. Chaouche, F. Ahmad, J.M. Armstrong, C. Piketty
doi : 10.1111/jdv.17218
Volume 35, Issue 7 p. 1562-1568
Nemolizumab is a humanized anti-IL-31 receptor blocker in phase 3 for atopic dermatitis (AD).
Towards a better understanding of adult idiopathic epidermal necrolysis: a retrospective study of 19 cases
P. Monnet, C. Rodriguez, O. Gaudin, P. Cirotteau, B. Papouin, O. Dereure, F. Tetart, S. Lalevee, A. Colin, B. Lebrun-Vignes, E. Abe, J.-C. Alvarez, V. Demontant, G. Gricourt, N. de Prost, C. Barau, O. Chosidow, P. Wolkenstein, S. Hue, N. Ortonne, B. Milpied, S. Ingen-Housz-Oro
doi : 10.1111/jdv.17274
Volume 35, Issue 7 p. 1569-1576
Most cases of Stevens–Johnson syndrome and toxic epidermal necrolysis are drug-induced. A small subset of cases remain with unknown aetiology (idiopathic epidermal necrolysis [IEN]).
Convergent Validity of Suffering and Quality of Life as Measured by The Hidradenitis Suppurativa Quality of Life
C. Kursawe Larsen, R. Kj?rsgaard Andersen, J. S. Kirby, J. Tan, D. M. L. Saunte, G. B. E. Jemec
doi : 10.1111/jdv.17148
Volume 35, Issue 7 p. 1577-1581
Hidradenitis suppurativa (HS) is a painful chronic, recurrent inflammatory skin disease with great impact on health-related quality of life (HRQOL). Recently, Hidradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC) established HRQOL as a core domain set for HS clinical trials and developed the Hidradenitis Suppurativa Quality of Life (HiSQOL) as a validated outcome measurement instrument.
Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic
D.M.L. Saunte, M. Pereiro-Ferreir?s, C. Rodr?guez-Cerdeira, A.Y. Sergeev, M. Arabatzis, A. Prohi?, B.M. Piraccini, P. Lecerf, P. Nenoff, L.P. Kotrekhova, P.P. Bosshard, V. Padovese, J.C. Szepietowski, B. Sigurgeirsson, R.J. Nowicki, P. Schmid-Grendelmeier, R.J. Hay
doi : 10.1111/jdv.17241
Volume 35, Issue 7 p. 1582-1586
Dermatophytosis is a world-wide distributed common infection. Antifungal drug resistance in dermatophytosis used to be rare, but unfortunately the current Indian epidemic of atypical widespread recalcitrant and terbinafine-resistant dermatophytosis is spreading and has sporadically been reported in Europe.
Randomized, double-blind, active-controlled, multicentre, phase III clinical trial with two stages to assess the safety and efficacy of letibotulinum toxin a vs. onabotulinum toxin a for subjects with moderate to severe crow's feet
K.H. Yoo, S.J. Park, H.S. Han, C.H. Won, Y.W. Lee, B.J. Kim
doi : 10.1111/jdv.17217
Volume 35, Issue 7 p. 1587-1594
Letibotulinum toxin A (LeBA) was approved by the Ministry of Food and Drug Safety (known as the Korea Food & Drug Administration) for cosmetic indications in 2012. However, the efficacy and safety of this newly introduced LeBA have not been investigated in crow's feet lines (CFL) treatment and standardization before its universal use.
Rapidly progressive alopecia areata totalis in a COVID-19 patient, unresponsive to tofacitinib
S. Berbert Ferreira, M.F.R. Gavazzoni Dias, R. Berbert Ferreira, A.C. Neves Neto, R.M. Trüeb, O. Lupi
doi : 10.1111/jdv.17170
Volume 35, Issue 7 p. e411-e412
Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic
M. Kasperkiewicz, E. Schmidt, M. Amagai, J.A. Fairley, P. Joly, D.F. Murrell, A.S. Payne, M.L. Yale, D. Zillikens, D.T. Woodley
doi : 10.1111/jdv.17207
Volume 35, Issue 7 p. e412-e414
Lichen planus arising after COVID-19 vaccination
I. Hiltun, J. Sarriugarte, I. Mart?nez-de-Espronceda, A. Garcés, C. Llanos, R. Vives, J.I. Yanguas
doi : 10.1111/jdv.17221
Volume 35, Issue 7 p. e414-e415
Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination
T. Gambichler, L. Scholl, H. Dickel, L. Ocker, R. Stranzenbach
doi : 10.1111/jdv.17225
Volume 35, Issue 7 p. e415-e416
Periocular capillaritis in a COVID-19-positive patient: report of a case
A. Paganelli, F. Garbarino, L. Bigi
doi : 10.1111/jdv.17227
Volume 35, Issue 7 p. e417-e418
COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation
M. Kasperkiewicz, M. Yale, R. Strong, D. Zillikens, D.T. Woodley, A. Recke
doi : 10.1111/jdv.17228
Volume 35, Issue 7 p. e418-e421
Follow-up of dermatological manifestations in non-critical hospitalized patients with COVID-19 pneumonia and their prognostic correlation with disease severity
A. Garc?a-Irigoyen, G.A. Acatitla-Acevedo, A. Barrera-God?nez, S. Méndez-Flores, J. Dom?nguez-Cherit
doi : 10.1111/jdv.17236
Volume 35, Issue 7 p. e421-e423
Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine
M. Ackerman, D. Henry, A. Finon, R. Binois, E. Esteve
doi : 10.1111/jdv.17248
Volume 35, Issue 7 p. e423-e425
Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. ‘COVID-arm’: a clinical and histological characterization
D. Fernandez-Nieto, J. Hammerle, M. Fernandez-Escribano, C.M. Moreno-del Real, P. Garcia-Abellas, I. Carretero-Barrio, E. Solano-Solares, B. de-la-Hoz-Caballer, J. Jimenez-Cauhe, D. Ortega-Quijano, M. Fernandez-Guarino
doi : 10.1111/jdv.17250
Volume 35, Issue 7 p. e425-e427
Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19
M. Arenbergerova, A. Lallas, E. Nagore, L. Rudnicka, A.M Forsea, M. Pasek, F. Meier, K. Peris, J. Olah, C. Posch
doi : 10.1111/jdv.17252
Volume 35, Issue 7 p. e427-e428
Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know
F. Diotallevi, A. Campanati, G. Radi, E. Martina, G. Rizzetto, P. Barbadoro, M.M. D'Errico, A. Offidani
doi : 10.1111/jdv.17256
Volume 35, Issue 7 p. e428-e430
A new virtual inpatient dermatology electronic referral service: a timely solution in the COVID-19 pandemic and beyond?
A. Lowe, A. Pararajasingam, F.M. Ali, S. Dawood, C.D. Lowe, N.M. Stone
doi : 10.1111/jdv.17257
Volume 35, Issue 7 p. e430-e432
Good tolerance of hyaluronic acid injections during the period of the COVID-19 pandemic: observing a cohort of 1093 patients in a prospective, observational real-life study
M. Naouri, S. Dahan, A. Le Pillouer Prost, P. Coutant-Foulc, C. Raimbault, F. Cucurella, L. Beille, M. Creusot, M. Baspeyras, M. Darchy, R. Khallouf, H. Cartier, I. Baratte, M. Dubois, O. Cogrel, H. Laubach, Groupe de Dermatologie Esthétique et Correctrice de la Société Française de Dermatologie (GDEC)
doi : 10.1111/jdv.17271
Volume 35, Issue 7 p. e432-e433
How to diagnose bullous pemphigoid and its variants: the question is still open
L. Borradori, K. Vinay, A. Bishnoi, S. Cazzaniga, P. Joly
doi : 10.1111/jdv.17214
Volume 35, Issue 7 p. e434-e435
Response to Letter to the editor of Borradori et al. How to diagnose bullous pemphigoid and its variants: the question is still open
J.M. Meijer, G.F.H. Diercks, H.H. Pas
doi : 10.1111/jdv.17213
Volume 35, Issue 7 p. e435-e436
Sensitive skin in China: characteristics and burden
M.K.T. Chan, M. Sayag, M. Chavagnac, C. Taieb, L. Misery
doi : 10.1111/jdv.17100
Volume 35, Issue 7 p. e436-e439
A case of PAPASH syndrome in a young man carrying a novel heterozygote missense variant in PSTPIP1
M. Kotzerke, F. Mitri, F. Marbach, A. Enk, H. Haenssle
doi : 10.1111/jdv.17171
Volume 35, Issue 7 p. e439-e440
Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting
S. Ribero, A. Ramondetta, G. Fabbrocini, V. Bettoli, C. Potenza, A. Chiricozzi, M. Licciardello, A.V. Marzano, L. Bianchi, G. Rozzo, L. Fania, C. Marasca, G. Odorici, A. Mambrin, C. Moltrasio, R.D. Caposiena Caro, N. Skroza, P. Quaglino, N. Siliquini, P. Dapavo
doi : 10.1111/jdv.17178
Volume 35, Issue 7 p. e441-e442
Design and evaluation of a multiplex vesicular rash PCR for the detection of varicella zoster virus and herpes simplex virus
B. Schmid, M. Affolter, A. Buttafuoco, P.P. Bosshard
doi : 10.1111/jdv.17198
Volume 35, Issue 7 p. e443-e444
mTORC1 – a potential player in the pathogenesis of hidradenitis suppurativa?
A. Dmitriev, A. K?nig, V. Lang, S. Diehl, R. Kaufmann, A. Pinter, C. Buerger
doi : 10.1111/jdv.17202
Volume 35, Issue 7 p. e444-e447
Successful treatment of pyoderma gangrenosum associated with IgA gammopathy with the IL-1 receptor antagonist anakinra
P. Rousset, P.M. Dugourd, A. Lanteri, H. Montaudié, T. Passeron
doi : 10.1111/jdv.17204
Volume 35, Issue 7 p. e447-e450
Lichen simplex chronicus of the scalp: dermoscopy and reflectance confocal microscopy features
M. Starace, V.D. Mandel, B. Francesca, A. Alessandrini, C. Misciali, Z. Apalla, M. Iorizzo, G. Pellacani, T. Silyuk, A. Patrizi, B.M. Piraccini
doi : 10.1111/jdv.17206
Volume 35, Issue 7 p. e450-e452
Low response of granulomatous cheilitis to currently established treatments
A. Kreuter, B. Koushk-Jalali, F. Oellig, C. Tigges
doi : 10.1111/jdv.17208
Volume 35, Issue 7 p. e453-e454
A real-world, observational study on the effectiveness with calcipotriol/betamethasone aerosol foam in patients with plaque psoriasis in Greece: the CELSUS study
D. Rigopoulos, E. Lazaridou, E. Papadavid, S. Georgiou, V. Chasapi, K. Sfaelos, G. Cheliotis, D. Ioannides
doi : 10.1111/jdv.17211
Volume 35, Issue 7 p. e454-e457
Low quality of life and high HSS-29 scores reflect the risk of loss to follow-up: a study in patients with androgenetic alopecia
J.Y. Lee, B.J. Kim, S.H. Lee, J.W. Lee, W.S. Lee
doi : 10.1111/jdv.17212
Volume 35, Issue 7 p. e457-e459
Eyelashes poliosis as first sign of metastatic melanoma
L. Burzi, M. Parietti, A. Agostini, E. Marra, M.T. Fierro, S. Ribero, P. Quaglino
doi : 10.1111/jdv.17215
Volume 35, Issue 7 p. e459-e460
Dermoscopic features of post kala azar dermal leishmaniasis
V. Thakur, P. Gupta, K. Vinay
doi : 10.1111/jdv.17222
Volume 35, Issue 7 p. e460-e462
Mesalazine-induced eosinophilic glossitis and hypereosinophilia in a patient with ulcerative colitis: a case report and review of literature
G. Smets, M. Grosber, J. Gutermuth, B. Bravenboer, B. Velkeniers
doi : 10.1111/jdv.17223
Volume 35, Issue 7 p. e462-e464
Dermoscopic patterns of green nail syndrome
J. Ohn, K. Hur, H. Park, S. Cho, J.-H. Mun
doi : 10.1111/jdv.17224
Volume 35, Issue 7 p. e464-e466
Characteristics of children with Netherton syndrome: a review of 21 patients
C. Prodinger, N. Yerlett, C. MacDonald, C. Subhanitthaya, M. Laimer, L. Goh, G. Du Toit, J.E. Mellerio, G. Petrof, A.E. Martinez
doi : 10.1111/jdv.17226
Volume 35, Issue 7 p. e466-e469
Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities
D. De, A. Kaushik, S. Handa, R. Mahajan, E. Schmidt
doi : 10.1111/jdv.17229
Volume 35, Issue 7 p. e469-e472
Pigtail hairs in syphilitic alopecia
T.F. Gomes, F. Santiago, V. Guiote
doi : 10.1111/jdv.17255
Volume 35, Issue 7 p. e472-e473
